Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics

被引:3
|
作者
Adesoye, Taiwo [1 ]
Tripathy, Debasish [2 ]
Hunt, Kelly K. [1 ]
Keyomarsi, Khandan [3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Div Canc Med, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
关键词
STAT3; cancer; therapeutics; EPIDERMAL-GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; DNA-BINDING ACTIVITY; HUMAN BREAST-CANCER; TRANSCRIPTION; SMALL-MOLECULE; CONSTITUTIVE ACTIVATION; COLORECTAL-CANCER; DECOY OLIGONUCLEOTIDE; DRUG-RESISTANCE;
D O I
10.3390/cancers16030492
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Signal Transducer and Activator of Transcription 3 (STAT3) is involved in many normal cellular processes that are tightly regulated. However, aberrant activation of STAT3 has been implicated in cancer development, recurrence, and metastasis in addition to development of resistance to therapy. Significant progress has been made in targeting STAT3 directly and indirectly through the development of novel therapeutic agents, although some drugs remain in the early phases of development, demonstrating promising potential for future clinical applications. There are several STAT3 inhibitors in clinical trials as monotherapy, and in combination with chemotherapeutic agents and biomarker analysis from these trials, will be critical to inform which patients will benefit from prolonged STAT3 inhibition.Abstract Signal Transducer and Activator of Transcription 3 (STAT3) plays a significant role in diverse physiologic processes, including cell proliferation, differentiation, angiogenesis, and survival. STAT3 activation via phosphorylation of tyrosine and serine residues is a complex and tightly regulated process initiated by upstream signaling pathways with ligand binding to receptor and non-receptor-linked kinases. Through downstream deregulation of target genes, aberrations in STAT3 activation are implicated in tumorigenesis, metastasis, and recurrence in multiple cancers. While there have been extensive efforts to develop direct and indirect STAT3 inhibitors using novel drugs as a therapeutic strategy, direct clinical application remains in evolution. In this review, we outline the mechanisms of STAT3 activation, the resulting downstream effects in physiologic and malignant settings, and therapeutic strategies for targeting STAT3. We also summarize the pre-clinical and clinical evidence of novel drug therapies targeting STAT3 and discuss the challenges of establishing their therapeutic efficacy in the current clinical landscape.
引用
收藏
页数:30
相关论文
共 50 条
  • [11] Role of STAT3 signaling pathway in breast cancer
    Jia-hui Ma
    Li Qin
    Xia Li
    [J]. Cell Communication and Signaling, 18
  • [12] Role of STAT3 signaling pathway in breast cancer
    Ma, Jia-hui
    Qin, Li
    Li, Xia
    [J]. CELL COMMUNICATION AND SIGNALING, 2020, 18 (01)
  • [13] Screening and biological evaluation of a novel STAT3 signaling pathway inhibitor against cancer
    Huang, Min
    Chen, Zhongjie
    Zhang, Lu
    Huang, Zhimin
    Chen, Yiying
    Xu, Jianrong
    Zhang, Jian
    Shu, Xiaohong
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (21) : 5172 - 5176
  • [14] STAT3 signaling in immunity
    Hillmer, Emily J.
    Zhang, Huiyuan
    Li, Haiyan S.
    Watowich, Stephanie S.
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2016, 31 : 1 - 15
  • [15] Novel STAT3 inhibitors targeting the STAT3 dimerization
    Hua, Yaping
    Azeem, Waqas
    Oyan, Anne Margrete
    Kalland, Karl-Henning
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [16] Immunohistochemical evaluation of Stat3 signaling and apoptosis in oral cancer
    Toutouzas, I.
    Nikitakis, N.
    Chrysomali, E.
    Sklavounou, A.
    [J]. ORAL DISEASES, 2012, 18 : 3 - 3
  • [17] STAT3 signaling in ovarian cancer: a potential therapeutic target
    Liang, Renba
    Chen, Xishan
    Chen, Li
    Wan, Fangzhu
    Chen, Kaihua
    Sun, Yongchu
    Zhu, Xiaodong
    [J]. JOURNAL OF CANCER, 2020, 11 (04): : 837 - 848
  • [18] Linking inflammation to cancer - A novel role for Stat3
    Ernst, Matthias
    Phesse, Toby J.
    Jenkins, Brendan
    Buchert, Michael
    McKenzie, Brent
    Bollrath, Julia
    Greten, Florian R.
    Putoczki, Tracy
    [J]. CYTOKINE, 2009, 48 (1-2) : 44 - 44
  • [19] Involvement of STAT3 Signaling in Proliferation of Pancreatic Cancer Cells
    Park, M.
    Lim, J. W.
    Kim, H.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (08) : 1660 - 1660
  • [20] Novel STAT3 inhibitor in the Treatment of Breast Cancer
    Senthil, M.
    Xing, Q.
    Yin, J.
    Buettner, R.
    Horne, D.
    Jove, R.
    Yim, J.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S50 - S50